METHODS	In an open-label , parallel-group trial , metformin-treated participants were randomised to liraglutide 1.2 mg/day ( n = 225 ) , liraglutide 1.8 mg/day ( n = 221 ) or sitagliptin 100 mg/day ( n = 219 ) for 26 weeks ( main phase ) .\